1605 related articles for article (PubMed ID: 27147749)
21. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
Pineo CB; Hitzeroth II; Rybicki EP
Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
[TBL] [Abstract][Full Text] [Related]
23. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
24. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
25. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
26. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
[TBL] [Abstract][Full Text] [Related]
27. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
28. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
29. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
Xu Y; Wang Q; Han Y; Song G; Xu X
J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
[TBL] [Abstract][Full Text] [Related]
30. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
31. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
[TBL] [Abstract][Full Text] [Related]
32. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
33. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
34. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
35. Development of an HPV vaccine for a broad spectrum of high-risk types.
Kanda T; Kondo K
Hum Vaccin; 2009; 5(1):43-5. PubMed ID: 18690012
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
Jagu S; Kwak K; Garcea RL; Roden RB
Vaccine; 2010 Jun; 28(28):4478-86. PubMed ID: 20434552
[TBL] [Abstract][Full Text] [Related]
37. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
Seitz H; Ribeiro-Müller L; Canali E; Bolchi A; Tommasino M; Ottonello S; Müller M
Cancer Prev Res (Phila); 2015 Oct; 8(10):932-41. PubMed ID: 26170394
[TBL] [Abstract][Full Text] [Related]
38. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
39. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
[TBL] [Abstract][Full Text] [Related]
40. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]